Thursday, December 13, 2012

Treatment of pancreatic adenocarcinoma


Medicineworld.org: Treatment of pancreatic adenocarcinoma


Subscribe To Pancreas RSS Feed  RSS content feed What is RSS feed?

Pancreatic ductal adenocarcinoma (PDAC) is a highly cancerous digestive tumor with a very poor prognosis. Hypoxia-inducible transcription factor-1a (HIF-1a) is involved in cancerous progression in a number of solid tumors, including PDAC, upregulation of HIF-1a accelerates PDAC progression, but the exact regulatory mechanisms of HIF-1ain PDAC has not been unequivocally addressed. Recently, an increasing number of studies reported that toll-like receptors (TLRs) were upregulated in epithelial malignancies and involved in tumor progression, but whether TLRs, such as TLR4, is expressed on PDAC cells remains unknown. In immune-related cells, TLR signal pathway may induce expression of HIF-1a, but it is also still unclear whether there exists some association between TLR4 and HIF-1a in tumor microenviroment, such as PDAC.
Treatment of pancreatic adenocarcinoma
A research article to be published on June 21, 2010 in the World Journal of Gastroenterology addresses this question. The research team led by He-Shui Wu, MD, from Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, used real time polymerase chain reaction and immunohistochemistry, to detect TLR4, NF-?B p65 and HIF-1a expression in 65 cases of PDAC tissues and 38 cases of corresponding adjacent tissues.

Their study revealed that TLR4, NF-?B p65 and HIF-1a were overexpressed in PDAC. The expression of TLR4 and HIF-1a was linked to tumor size, lymph node metastasis, venous invasion and pathological stage. Furthermore, the expression of TLR4 was positively correlated with expression of HIF-1a. Thus, TLR4 appears to be a novel marker for the progression and prognosis of PDAC, and may provide a new strategy for therapeutic intervention in the therapy of patients with PDAC in the future.

Based on these results and prior reports, the authors speculated that active TLR4 signal pathway appears to be partly involved in up-regulating HIF-1a in PDAC tumor microenviroment via NF-?B pathway, and promoted progression of PDAC. These results demonstrated a new view of molecules involved in regulatory mechanism of HIF-1a and thus may provide new therapeutic targets for PDAC.

Posted by: Sue    Source


Did you know?
Pancreatic ductal adenocarcinoma (PDAC) is a highly cancerous digestive tumor with a very poor prognosis. Hypoxia-inducible transcription factor-1and#945; (HIF-1and#945;) is involved in cancerous progression in a number of solid tumors, including PDAC, upregulation of HIF-1and#945; accelerates PDAC progression, but the exact regulatory mechanisms of HIF-1and#945;in PDAC has not been unequivocally addressed. Recently, an increasing number of studies reported that toll-like receptors (TLRs) were upregulated in epithelial malignancies and involved in tumor progression, but whether TLRs, such as TLR4, is expressed on PDAC cells remains unknown. In immune-related cells, TLR signal pathway may induce expression of HIF-1and#945;, but it is also still unclear whether there exists some association between TLR4 and HIF-1and#945; in tumor microenviroment, such as PDAC.
Medicineworld.org: Treatment of pancreatic adenocarcinoma

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.  

View the original article here

No comments:

Post a Comment